Look­ing to re­tain its run­ner-up po­si­tion in HIV, Mer­ck scores two new ap­provals for HIV ther­a­pies

Mer­ck $MRK scored two new drug OKs in HIV, of­fer­ing a pair of an­ti­retro­vi­ral ther­a­pies to pa­tients. But they’re un­like­ly to of­fer much of a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.